North Dakota is currently home to 210 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Fargo, Bismarck, Grand Forks and Minot. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
NCT05001880
Recruiting
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Sanford Bismarck Medical Center, Bismarck, North Dakota
Conditions: Peritoneal Malignant Mesothelioma
Register for Updates
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311
Recruiting
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0138), Fargo, North Dakota
Conditions: Gastroesophageal Cancer
Register for Updates
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Arthrosi Investigative Site (666), Fargo, North Dakota
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Register for Updates
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: Sanford Broadway Medical Center, Fargo, North Dakota
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Register for Updates
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123
Recruiting
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Fargo, North Dakota
Conditions: Cardiovascular Disease
Register for Updates
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
NCT06924021
Recruiting
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/21/2025
Locations: Bergstrom Eye Research LLC, Fargo, North Dakota
Conditions: Age-Related Macular Degeneration
Register for Updates
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103
Recruiting
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
07/18/2025
Locations: Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo, North Dakota
Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Register for Updates
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893
Recruiting
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708), Fargo, North Dakota
Conditions: Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Register for Updates
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869
Recruiting
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Lillestol Research LLC, Fargo, North Dakota
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Register for Updates
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
NCT02418442
Recruiting
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/15/2025
Locations: Sanford Health, Fargo, North Dakota
Conditions: Rheumatic Joint Disease
Register for Updates
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
NCT03998202
Recruiting
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/14/2025
Locations: Sanford Bismarck Medical Center, Bismarck, North Dakota
Conditions: Colorectal Cancer, Sarcopenia
Register for Updates
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455
Recruiting
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Sanford Broadway Medical Center, Fargo, North Dakota
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Register for Updates